Literature DB >> 22273058

Patient preferences for an oral anticoagulant after major orthopedic surgery: results of a german survey.

Thomas Wilke1.   

Abstract

BACKGROUND: Since 2008, the availability of the oral direct thrombin inhibitor dabigatran etexilate provides a further therapeutic alternative to injectable low-molecular-weight heparin (LMWH) for thromboprophylaxis following hip or knee replacement surgery. The intention of this study is to analyze patient preferences for this new oral thromboprophylaxis agent.
METHODS: Face-to-face interviews were conducted with 73 doctors and nurses in 12 German hospitals, 195 current hip and knee replacement patients in six German rehabilitation hospitals, and 202 former thromboprophylaxis patients. Qualitative questions were complemented by a full-profile ranking-based conjoint analysis regarding alternative thromboprophylaxis regimens.
RESULTS: Nearly 100% of the interviewed medical staff viewed the daily subcutaneous LMWH injection as a source of inconvenience for patients. However, both current and former patients perceived their discomfort to be much less intense. In contrast, the conjoint estimates of preferences showed that older and male patients in particular understated their levels of discomfort in a face-to-face interview situation and had a strong preference for oral anticoagulation.
CONCLUSIONS: Patients in Germany appear to have a positive preference for oral thromboprophylaxis after major orthopedic surgery.

Entities:  

Year:  2009        PMID: 22273058     DOI: 10.2165/01312067-200902010-00005

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  11 in total

Review 1.  Anticoagulation: the present and future.

Authors:  H Van Aken; C Bode; H Darius; C Diehm; A Encke; D C Gulba; S Haas; W Hacke; W Puhl; M Quante; H Riess; R Scharf; S Schellong; T Schrör; K L Schulte; U Tebbe
Journal:  Clin Appl Thromb Hemost       Date:  2001-07       Impact factor: 2.389

2.  A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

Authors:  B I Eriksson; O E Dahl; H R Büller; R Hettiarachchi; N Rosencher; M-L Bravo; L Ahnfelt; F Piovella; J Stangier; P Kälebo; P Reilly
Journal:  J Thromb Haemost       Date:  2005-01       Impact factor: 5.824

Review 3.  New versus established drugs in venous thromboprophylaxis: efficacy and safety considerations related to timing of administration.

Authors:  Bruno Tribout; Florence Colin-Mercier
Journal:  Am J Cardiovasc Drugs       Date:  2007       Impact factor: 3.571

Review 4.  [Prevention of thrombosis in hip prosthesis implantation].

Authors:  F Böttner; T P Sculco; N E Sharrock; G H Westrich; J Steinbeck
Journal:  Orthopade       Date:  2001-11       Impact factor: 1.087

5.  Patient non-compliance: deviance or reasoned decision-making?

Authors:  J L Donovan; D R Blake
Journal:  Soc Sci Med       Date:  1992-03       Impact factor: 4.634

6.  Thromboprophylaxis in orthopedic surgery.

Authors:  Clifford W Colwell
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2006-06

Review 7.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  Conducting discrete choice experiments to inform healthcare decision making: a user's guide.

Authors:  Emily Lancsar; Jordan Louviere
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  [Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals].

Authors:  T Wilke; K Neumann; U Klapper; I Messer; A Werner; U Seidel; D Röleke
Journal:  Orthopade       Date:  2008-05       Impact factor: 1.087

10.  Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

Authors:  Bengt I Eriksson; Ola E Dahl; Nadia Rosencher; Andreas A Kurth; C Niek van Dijk; Simon P Frostick; Martin H Prins; Rohan Hettiarachchi; Stefan Hantel; Janet Schnee; Harry R Büller
Journal:  Lancet       Date:  2007-09-15       Impact factor: 79.321

View more
  11 in total

1.  Postoperative Thromboprophylaxis With New Oral Anticoagulants is Superior to LMWH in Hip Arthroplasty Surgery: Findings from the Swedish Registry.

Authors:  Piotr Kasina; Alexander Wall; Lasse J Lapidus; Ola Rolfson; Johan Kärrholm; Szilard Nemes; Bengt I Eriksson; Maziar Mohaddes
Journal:  Clin Orthop Relat Res       Date:  2019-06       Impact factor: 4.176

2.  Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery.

Authors:  Thomas Wilke; Jörn Moock; Sabrina Müller; Matthias Pfannkuche; Andreas Kurth
Journal:  Clin Orthop Relat Res       Date:  2010-03-24       Impact factor: 4.176

3.  Shared Decision Making: From Decision Science to Data Science.

Authors:  Azza Shaoibi; Brian Neelon; Leslie A Lenert
Journal:  Med Decis Making       Date:  2020-02-06       Impact factor: 2.583

4.  [Patient pathways in thrombosis prophylaxis after hip and knee replacement surgery : results of a survey].

Authors:  S Müller; T Wilke; M Pfannkuche; I Meber; A Kurth; H Merk; F Steinfeldt; D Ganzer; C Perka
Journal:  Orthopade       Date:  2011-07       Impact factor: 1.087

5.  Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis.

Authors:  Kathrin S Utz; Jana Hoog; Andreas Wentrup; Sebastian Berg; Alexandra Lämmer; Britta Jainsch; Anne Waschbisch; De-Hyung Lee; Ralf A Linker; Thomas Schenk
Journal:  Ther Adv Neurol Disord       Date:  2014-11       Impact factor: 6.570

Review 6.  Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.

Authors:  Brett T Venker; Beejal R Ganti; Hannah Lin; Elizabeth D Lee; Ryan M Nunley; Brian F Gage
Journal:  J Arthroplasty       Date:  2016-10-05       Impact factor: 4.757

Review 7.  Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.

Authors:  Christina L Fanola
Journal:  Vasc Health Risk Manag       Date:  2015-05-27

8.  The compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery.

Authors:  Yuan Gao; Anhua Long; Zongyan Xie; Yutong Meng; Jing Tan; Houchen Lv; Licheng Zhang; Lihai Zhang; Peifu Tang
Journal:  Springerplus       Date:  2016-08-18

9.  Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.

Authors:  Andréa Senay; Milanne Trottier; Josée Delisle; Andreea Banica; Benoit Benoit; G Yves Laflamme; Michel Malo; Hai Nguyen; Pierre Ranger; Julio C Fernandes
Journal:  Vasc Health Risk Manag       Date:  2018-05-08

10.  Patients' perception about risks and benefits of antithrombotic treatment for the prevention of venous thromboembolism (VTE) after orthopedic surgery: a qualitative study.

Authors:  M Najafzadeh; S C Kim; C Patterson; S Schneeweiss; J N Katz; G W Brick; J E Ready; J M Polinski; E Patorno
Journal:  BMC Musculoskelet Disord       Date:  2015-10-26       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.